#United States #Los Angeles #Lung Cancer #LUNGevity Foundation #AI Algorithms

Transforming Lung Cancer Detection

In a landmark announcement made on September 29, 2026, LUNGevity Foundation, the leading nonprofit organization focused on lung cancer, revealed its support for two pioneering research initiatives. These projects target the critical challenge of accurately diagnosing indeterminate pulmonary nodules (IPNs), which are small abnormalities seen on chest CT scans that may indicate the presence of lung cancer.

Each year, over 1.5 million Americans receive the distressing news that they have an IPN. Unfortunately, current non-invasive diagnostic methods frequently fail to provide clarity, resulting in a great deal of confusion, prolonged anxiety, and unnecessary invasive procedures for many patients. Recognizing this unmet need in pulmonary medicine, LUNGevity has launched a strategic collaboration with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) to develop innovative tools aimed at improving the early detection of lung cancer.

The Upcoming Studies

The two studies, funded through the newly established 2026 RTFCCR/LUNGevity Early Detection Award, represent a collective effort to leverage advanced technology for better patient outcomes. Each project introduces unique methodologies aimed at evaluating a patient's risk of developing lung cancer more effectively.

Study 1: Integrated Radiomic and Cell-Free DNA Approach

Led by Dr. Steven Dubinett from the University of California, Los Angeles, this ambitious study will incorporate a combination of advanced CT imaging and a blood-based test to assess the probability that an indeterminate nodule is malignant. The research team plans to validate its approach on a cohort of 500 patients across various healthcare facilities, including UCLA and Veterans Affairs hospitals. The aim is to furnish clinicians with dependable, non-invasive diagnostic tools that ensure early identification and treatment of potentially cancerous nodules.

Study 2: The RESOLVE Study

Conversely, Dr. Lecia Sequist from Massachusetts General Hospital/Harvard Medical School spearheads the RESOLVE Study, which seeks to evaluate a cutting-edge artificial intelligence model, Sybil. This groundbreaking AI system is designed to estimate lung cancer risk based directly on CT scans, eliminating the need for human interpretation. The study will involve 340 adults aged between 35 to 75 who are identified as low-risk for pulmonary nodules, with a focus on assessing AI's real-world performance in diverse clinical settings.

Anticipated Impact

Both studies aim to revolutionize lung cancer detection in several critical ways:

• - Reducing Unnecessary Procedures: By establishing more accurate diagnostic criteria, these initiatives have the potential to significantly lessen the number of unnecessary biopsies and surgeries that patients currently face.
• - Improving Access to Early Detection: The advancements could provide a lifeline to populations traditionally underrepresented in lung cancer statistics, particularly women without standard risk factors who are increasingly being diagnosed.
• - Facilitating Timely Interventions: Accelerating the identification of high-risk individuals could result in quicker follow-ups and interventions, further enhancing treatment outcomes.

Expert Insights

Dr. Upal Basu Roy, the executive director of LUNGevity Research, highlighted the dual focus on patient and clinical utility in both projects. He expressed pride in partnering with Rising Tide Foundation to create reliable tools that would bring certainty to patients and their families experiencing the anxiety of an inconclusive diagnosis.

Dr. Zoraide Granchi of RTFCCR emphasized the necessity of visionary science that can elevate standards of patient care. Each of the project leaders is recognized as a leading authority in lung cancer research, with contributions from expert patient partners enhancing the studies’ relevance and reach.

The LUNGevity Foundation has expressed gratitude for the ongoing support of Upstage Lung Cancer in backing critical early detection research, underscoring the collaborative spirit necessary to tackle this complex issue effectively.

About the Organizations

Founded in 2010 and headquartered in Schaffhausen, Switzerland, the Rising Tide Foundation for Clinical Cancer Research aims to propel patient-centered research that leads to earlier detection and improved therapies for cancer patients. Meanwhile, LUNGevity Foundation stands at the forefront of transforming diagnoses and treatment for those living with lung cancer, dedicated to promoting health equity and amplifying patients’ voices through advocacy and community engagement.

For more detailed information on LUNGevity Foundation and its critical initiatives, visit www.LUNGevity.org.